Skip to main content
. Author manuscript; available in PMC: 2020 Nov 14.
Published in final edited form as: Leukemia. 2020 May 14;34(11):2981–2991. doi: 10.1038/s41375-020-0858-1

Figure 2. CM activates STAT3 and STAT5 in AML cells and knockdown of STAT5 is associated with impaired cell growth in FLT3-ITD+ AML.

Figure 2.

A. Immunoblots demonstrate STAT3 and STAT5 activation in AML cell lines cultured in RM and CM. B and C. Patterns of STAT3 and STAT5 activation in CD34+ cells from patients with FLT3-ITD+ and FLT3-ITD− AML. D. MOLM-13 cells containing an empty vector or shRNA constructs targeting STAT3, STAT5 or both STAT3 and STAT5 were cultured in RM or CM and treated with graded concentrations of quizartinib. Cell proliferation was measured at 72 hours. (n=3)